Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Sopharma AD-Sofia's Total Liabilities for the quarter that ended in Jun. 2026 was €527 Mil. Sopharma AD-Sofia's Total Assets for the quarter that ended in Jun. 2026 was €1,081 Mil.
Therefore, Sopharma AD-Sofia's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.49.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Sopharma AD-Sofia Liabilities-to-Assets Related Terms
Sopharma AD-Sofia Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3JR vs MCK, COR, CAH: Liabilities-to-Assets Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Liabilities-to-Assets vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Sopharma AD-Sofia's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (FRA:3JR) has a Liabilities-to-Assets of 0.49 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Liabilities-to-Assets too high?
Sopharma AD-Sofia's current Liabilities-to-Assets is 0.49. Overall, Sopharma AD-Sofia has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Liabilities-to-Assets compare to MCK and COR?
Sopharma AD-Sofia's Liabilities-to-Assets of 0.49 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Distribution company?
A good Liabilities-to-Assets depends on the Medical Distribution industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Liabilities-to-Assets is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Sopharma AD-Sofia (FRA:3JR) has a current Liabilities-to-Assets of 0.49. The stock's GF Value™ is €2.06, compared to a current price of €2.15 — trading 4.4% above its estimated fair value. The current Liabilities-to-Assets is 0.49. Sopharma AD-Sofia's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Sopharma AD-Sofia (FRA:3JR), the current Liabilities-to-Assets is 0.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (FRA:3JR) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be overvalued.
The current stock price of €2.15 is trading 4.4% above its estimated GF Value™ of €2.06.
Key valuation signals for FRA:3JR:
Liabilities-to-Assets: 0.49
GF Value™: €2.06 vs. price of €2.15 (4.4% above fair value)
No single metric tells the full story. See the FRA:3JR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
55GF Score
Get the complete analysis for FRA:3JR
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3JR has been successfully added to your 
